{"prompt": "['Alliance A171601', '22.', 'Kimmick G, Fleming R, Muss H, et al: Cancer chemotherapy in older adults: A tolerability', 'perspective. Drugs Aging 10:34-49, 1997', '23.', 'BalducciL Corcoran M: Antineoplastic chemotherapy of the older cancer patient. Hematol', 'Oncol Clin N Am 14:193-212, 2000', '24.', 'Maione P, Perrone F, Gallo C, et al: Pretreatment quality of life and functional status assessment', 'significantly predict survival of elderly patients with advanced non-small-cell lung cancer', 'receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer study in the', 'elderly study. J Clin Oncol 123:6865-6872, 2005', '25.', 'Freyer G, Geay J, Touzet S, et al: Comprehensive geriatric assessment predicts tolerance to', 'chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO', 'study. Ann Oncol 16:1795-1800, 2005', '26.', 'Repetto L, Fratino L, Audisio R, et al: Comprehensive geriatric assessment adds information to', 'Eastern Cooperative Group performance status in elderly cancer patients; an Italian Group for', 'Geriatric Oncology Study. J Clin Oncol 20:494-502, 2002', '27.', 'Rao A, Hsieh F, Feusser J, et al: Geriatric evaluation and management units in the care of the frail', 'elderly patient. J Gerontol A Biol Sci Med Sci 60:798-803, 2005', '28.', 'Extermann M, Aapro M, Bernabei R, et al: Use of coprehensive geriatric assessment in older', 'cancer patients: recommendation from the task force on CGA of the International Society of', 'Geriatric Oncology. Crit Rev Oncol Hematol 55:241-252, 2005', '29.', 'Giacinti C, Giordano A: RB and cell cycle progression. Oncogene 25:5220-7, 2006', '30', 'Finn, R.S. et al: Primary results from a phase III trial of palbociclib (P) with letrozole (L)', 'compared with letrozole alone in postmenopausal women with ER+/HER2- - advanced breast', 'cancer (ABC). NEJM 2016', '31.', 'Crown J, Finn RS, Ettl J, et al: Efficacy and safety of first-line palbociclit plus letrozole', 'compared with letrozole alone in patients aged >= 65 years with estrogen receptor-positive,', 'HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18', 'trial. Journal of Clinical Oncology 33, 2015', '32.', 'Slamon DJ, Crown J, Lang I, et al: Long-term safety profile of palbociclib (P) in combination', 'with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2-', 'advanced breast cancer (ABC) (PALOMA-1/TRIO-18). Journal of Clinical Oncology 33, 2015', '33', 'Visser M, Goodpaster BH, Kritchevsky SB, et al. Muscle mass, muscle strength, and muscle fat', 'infiltration as predictors of incident mobility limitations in well-functioning older persons. The', 'journals of gerontology. Series A, Biological sciences and medical sciences. 2005;60(3):324-333', '34', 'Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older', 'persons is associated with functional impairment and physical disability. Journal of the American', 'Geriatrics Society. 2002;50(5):889-896.', '35.', 'Rolland Y, Czerwinskis Abellan Van Kan G, et al. Sarcopenia: its assessment, etiology,', 'pathogenesis, consequences and future perspectives. The journal of nutrition, health & aging.', '2008;12(7):433-450.', '36.', 'Metter EJ, Conwit] R, Tobin J, Fozard JL. Age-associated loss of power and strength in the upper', 'extremities in women and men. The journals of (gerontology. Series A, Biological sciences and', 'medical sciences. 1997;52(5):B267-276.', '37.', 'Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. The American journal of', 'clinical nutrition. 2010;91(4):1123S-1127S.', '38.', 'Molina-Garrido MJ, Guillen-Ponce C, Fernandez-Felix BM. Relationship Between Sarcopenia', 'and Frailty in a Spanish Cancer in the Elderly Unit: The ONCOSARCO Project. Journal of the', 'American Medical Directors Association. 2016;17(8):760-761', '78', 'NCI Version Date: 5/29/2020', 'Update 5']['Alliance A171601', '39.', 'Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer', 'cachexia. Nat Rev Clin Oncol. 2013;10(2):90-99.', '40.', 'Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793-', '799.', '41.', 'Weinberg M, Shachar S, Deal A, et al. Characterization of skeletal muscle and body mass indices', 'in younger and older women with stage II and III breast cancer. Journal of the American', 'Geriatrics Society. 2016;supplement:S86.', '42.', 'Strulov Shachar S, Deal AM, Weinberg M, et al. Skeletal Muscle Measures as Predictors of', 'Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving', 'Taxane Based Chemotherapy. Clinical cancer research : an official journal of the American', 'Association for Cancer Research. 2016.', '43.', 'Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. Apractical and', 'precise approach to quantification of body composition in cancer patients using computed', 'tomography images acquired during routine care. Appl Physiol Nutr Me. 2008;33(5):997-1006.', '44.', 'Aubrey J, EsfandiariN, Baracos VE, et al. Measurement of skeletal muscle radiation attenuation', 'and basis of its biological variation. Acta physiologica. 2014;210(3):489-497.', '45', 'Shaw JW, Johnson JA, Coons SJ (2005). US valuation of the EQ-5D health states: development', 'and testing of the D1 valuation model. Med Care; 43(3): 203-220', '46', 'Rock, E. P., D. L. Kennedy, et al. (2007). \"Patient-reported outcomes supporting anticancer', 'product approvals.\" J Clin Oncol 25(32): 5094-5099.', '47', 'Basch, E., X. Jia, et al. (2009). \"Adverse symptom event reporting by patients VS clinicians:', 'relationships with clinical outcomes.\" J Natl Cancer Inst 101(23): 1624-1632.', '48', 'Fromme, E. K., K. M. Eilers, et al. (2004). \"How accurate is clinician reporting of chemotherapy', 'adverse effects? Acomparison with patient-reported symptoms from the Quality-of-Life', 'Questionnaire C30.\" J Clin Oncol 22(17): 3485-3490.', '49', 'Petersen, M. A., H. Larsen, et al. (2006). \"Assessing health-related quality of life in palliative', 'care: comparing patient and physician assessments.\" Eur J Cancer 42(8): 1159-1166.', '50', 'Rabin, R. and F. de Charro (2001). \"EQ-5D: a measure of health status from the EuroQol Group.\"', 'Ann Med 33(5): 337-343.', '51', 'Herdman, M., C. Gudex, et al. (2011). \"Development and preliminary testing of the new five-', 'level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10): 1727-1736.', '52', 'Hurria A, Cirrincione CT, Muss HB, et al: Implementing a geriatric assessment in cooperative', 'group clinical cancer trials: CALGB 360401. J Clin Oncol 29:1290-6, 2011', '53.', 'Repetto L, Fratino L, Audisio RA, et al: Comprehensive geriatric assessment adds information to', 'Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian', 'Group for Geriatric Oncology Study. J Clin Oncol 20:494-502, 2002', '54.', 'Kimmick GG, Fleming R, Muss HB, et al: Cancer chemotherapy in older adults. A tolerability', 'perspective. Drugs Aging 10:34-49, 1997', '55.', 'Maione P, Perrone F, Gallo C, et al: Pretreatment quality of life and functional status assessment', 'significantly predict survival of elderly patients with advanced non-small-cell lung cancer', 'receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly', 'study. J Clin Oncol 23:6865-72, 2005', '56.', 'Extermann M, Aapro M, Bernabei R, et al: Use of comprehensive geriatric assessment in older', 'cancer patients: recommendations from the task force on CGA of the International Society of', 'Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241-52, 2005', '79', 'NCI Version Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}